Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized Rater-Blinded 6-Month Head-To-Head Trial to Evaluate the Safety and Tolerability of Paliperidone ER Versus Olanzapine in Patients With Schizophrenia.

Trial Profile

A Prospective Randomized Rater-Blinded 6-Month Head-To-Head Trial to Evaluate the Safety and Tolerability of Paliperidone ER Versus Olanzapine in Patients With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Paliperidone (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Jun 2012 Results published in the Journal of Clinical Psychopharmacology.
    • 14 Sep 2010 US FDA approved NDA for paliperidone for the acute and maintenance treatment of schizophrenia based data from this and other pivotal trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top